Medical care expenditures for hypertension, its complications, and its comorbidities

Medical Care

Volumn 39, Issue 6, 2001, Pages 599-615

  Hodgson, Thomas A ^a   Cai, Liming ^b  

^a NATIONAL CENTER FOR HEALTH STATISTICS   (United States)

^b NOVA Research Company   (United States)

Author keywords

Costs; Expenditures; Hypertension

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COMORBIDITY; COMPARATIVE STUDY; COST OF ILLNESS; ECONOMICS; FEMALE; GOVERNMENT; HEALTH CARE COST; HEALTH SERVICES RESEARCH; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; STATISTICS; UNITED STATES;

ADULT; AGED; CARDIOVASCULAR DISEASES; COMORBIDITY; COST OF ILLNESS; FEMALE; HEALTH EXPENDITURES; HEALTH SERVICES RESEARCH; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; UNITED STATES; UNITED STATES CENTERS FOR MEDICARE AND MEDICAID SERVICES;

EID: 0035374641     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005650-200106000-00008     Document Type: Article

References (60)

1. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population - results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995;25:305-313.
2. National Center for Health Statistics. Health, United States, with Health and Aging Chartbook. Hyattsville, Md: National Center for Health Statistics; 1999.
3. Meissner I, Whisnant JP, Sheps SG, et al. Detection and control of high blood pressure in the community. Hypertension 1999;34:466-471.
4. Berlowitz DR, Ash AS, Mickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998;339:1957-1963.
5. Ogden LG, He J, Lydick E, et al. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension 2000;35:539-543.
6. Lloyd-Jones DM, Evans JC, Larson MG, et al. Differential impact of systolic and diastolic blood pressure level on JNC-VI staging. Hypertension 1999;34:381-387.
7. Hodgson TA, Cohen AJ. Medical care expenditures for selected circulatory diseases - opportunities for reducing national health expenditures. Med Care 1999;37:994-1012.
8. Cowan CA, Lazenby HC, Martin AB, et al. National health expenditures, 1998. Health Care Financ Rev 1999;21(2):165-211.
9. Ginsberg PB, Pickreign JD. Tracking health care costs. Health Aff 1996;15(3):140-149.
10. Mitchell JB, Bubolz T, Paul JE, et al. Using Medicare claims for outcomes research. Med Care 1994;32:JS38-JS51.
11. Graves EJ, Kozak LJ. National Hospital Discharge Survey: annual summary, 1996. National Center for Health Statistics. Series 13, issue 140. Vital Health Stat 1999:1-5.
12. Benson V, Marano MA. Current estimates from the National Health Interview Survey, 1995. National Center for Health Statistics. Series 10, issue 199. Vital Health Stat 1998:77-78.
13. Schappert SM. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 1996. National Center for Health Statistics. Series 13, issue 134. Vital Health Stat 1998:1-3.
14. Jones A, Strahan G. The National Home and Hospice Care Survey: 1994 summary. National Center for Health Statistics. Series 13, issue 126. Vital Health Stat 1997:87.
15. Gabrel C, Jones A. The National Nursing Home Survey 1995 summary. National Center for Health Statistics. Series 13, issue 146. Vital Health Stat 2000:1-3.
16. Edwards W, Berlin M. Questionnaires and data collection methods for the Household Survey and the Survey of American Indians and Alaska Natives. National Medical Expenditure Survey Methods 2. Rockville, MD: National Center for Health Services, Research, and Health Care Technology Assessment; 1989:1-8.
17. IMS America. Information services manual. Plymouth Meeting, PA: 1994:18.1-19.50.
18. Public Health Service and Health Care Financing Administration. International Classification of Diseases, 9th Revision, clinical modification. Washington, DC: Public Health Service; 1980.
19. Hodgson TA, Cohen AJ. Medical care expenditures for diabetes, its chronic complications, and its comorbidities. Prev Med 1999;29:173-186.
20. Ray NF, Thamer M, Gardner E, et al. Economic consequences of diabetes mellitus in the US in 1997. Diabetes Care 1998;21:296-309.
21. Hall WD, Ferrario CM, Moore MA, et al. Hypertension-related morbidity and mortality in the southeastern United States. Am J Med Sci 1997;313:195-209.
22. National Heart, Lung, and Blood Institute. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Washington, DC: National Institutes of Health, 1997.
23. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996;334:13-418.
24. Benichou J, Chow WH, McLaughlin JK, et al. Population attributable risk of renal cell cancer in Minnesota. Am J Epidemiol 1998;148:424-430.
25. Mange KC, Cizman B, Joffe M, et al. Arterial hypertension and renal allograft survival. JAMA 2000;283:633-638.
26. Davies SJC, Ghahramani P, Jackson PR, et al. Association of panic disorder and panic attacks with hypertension. Am J Med 1999;107:310-316.
27. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-1483.
28. Oates JA. Antihypertensive agents and the drug therapy of hypertension. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. New York, NY: McGraw-Hill; 1996: 780-808.
29. Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000;342:905-912.
30. McKeigue PM, Reynard JM. Relation of nocturnal polyuria of the elderly to essential hypertension. Lancet 2000;355:486-488.
31. Stewart RB, Moore MT, May FE, et al. Nocturia: a risk factor for falls in the elderly. J Am Geriatr Soc 1992;40:1217-1220.
32. Rice DP. Estimating the cost of illness. Health Economics Series Number 6. Washington, DC: Public Health Service; 1966.
33. Cooper BS, Rice DP. The economic cost of illness revisited. Soc Secur Bull 1976;39(2):21-36.
34. Berk A, Paringer L, Mushkin SJ. The economic cost of illness fiscal 1975. Med Care 1978;16:785-790.
35. Hodgson TA, Kopstein AN. Health care expenditures for major diseases in 1980. Health Care Financ Rev 1984;5(4):1-12.
36. Rice DP, Hodgson TA, Kopstein AN. The economic costs of illness: A replication and update. Health Care Financ Rev 1985;7(1):61-80.
37. Hodgson TA, Cohen AJ. Medical expenditures for major diseases, 1995. Health Care Financ Rev 1999;21(2):119-164.
38. Gardocki GJ, McLemore T, DeLozier JE. The National Ambulatory Med Care Complement Survey: United States, 1980. National Center for Health Statistics. Series 13, issue 77. Vital Health Stat 1984:5-7.
39. Miller ME, Zuckerman S, Gates M. How do Medicare physician fees compare with private payers? Health Care Financ Rev 1993;14(3):25-39.
40. Byerly E, Deardorff K. National and state population estimates: 1990-1994. Current Population Reports. Series P-25, no. 1127:1-70. Washington, DC: US Department of Commerce; July 1995.
41. Edwards WS, Winn DM, Kurlantzick V, et al. Evaluation of National Health Interview Survey diagnostic reporting. National Center for Health Statistics. Series 2, issue 120. Vital Health Stat 1994:34.
42. Vargas CM, Burt VL, Gillum RF, et al. Validity of self-reported hypertension in the National Health and Nutrition Examination Survey III, 1988-1991. Prev Med 1997:26:678-685.
43. Bruzzi P, Green SB, Byar DP, et al. Estimating the population attributable risk for multiple risk factors using case-control data. Am J Epidemiol 1985;122:904-914.
44. Shah BV, Barnwell BG, Bieler GS. SUDAAN user's manual release 7.0. Research Triangle Park, NC: Research Triangle Institute; 1996.
45. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes JAMA 1998;280:1690-1691.
46. National Center for Health Statistics. Health, United States, 2000 with Adolescent Health Chartbook. Hyattsville, Md: National Center for Health Statistics, 2000.
47. Adams PF, Hendershot GE, Marano MA. Current estimates from the National Health Interview Survey, 1996. National Center for Health Statistics. Series 10, issue 200. Vital Health Stat 1999:84-96.
48. Collins JG. Prevalence of selected chronic conditions: United States, 1990-92. National Center for Health Statistics. Series 10, issue 194. Vital Health Stat 1997:4-5.
49. He J, Whelton PK, Appel LJ, et al. Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension 2000;35:544-549.
50. Boysen G. Medical intervention: clinical trials and population-based observational outcomes. In: Whisnant JP, editor. Stroke: populations, cohorts, and clinical trials. Oxford: Butterworth-Heinemann: 1993; 187-207.
51. National Task Force on the Prevention and Treatment of Obesity. Overweight, obesity, and health risk. Arch Intern Med 2000;160:898-904.
52. Hahn RA, Heath GW, Chang MH. Cardiovascular disease risk factors and preventive practices among adults-United States, 1994: a behavioral risk factor atlas. MMWR 1998;47(SS5):35-48.
53. Cooper ME, Johnston CI. Optimizing treatment of hypertension in patients with diabetes. JAMA 2000;283(24):3177-3179.
54. Chrisp P, Lewis NJW, Milne RJ. Simvastatin a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease. PharmacoEconomics 1992;1:124-145.
55. Hodgson TA. Costs of illness in cost-effectiveness analysis: a review of the methodology. PharmacoEconomics 1994;6:536-552.
56. Hodgson TA. Annual costs of illness versus lifetime costs of illness and implications of structural change. Drug Information J 1988;22:323-341.
57. Hodgson TA. Cigarette smoking and lifetime medical expenditures. Milbank Q 1992;70:81-125.
58. Hjalte K, Lindgren B, Persson U. Cost-effectiveness of simvastatin versus cholestyramine results for Sweden. PharmacoEconomics 1992;1:213-216.
59. Ford ES, Kelly AE, Teutsch SM, et al. Radon and lung cancer: a cost-effectiveness analysis. Am J Public Health 1999;89:351-357.
60. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York, NY: Oxford University Press; 1996.